|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Yugawa T and Kiyono T: Molecular
mechanisms of cervical carcinogenesis by high-risk human
papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev
Med Virol. 19:97–113. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bozic I, Antal T, Ohtsuki H, Carter H, Kim
D, Chen S, Karchin R, Kinzler KW, Vogelstein B and Nowak MA:
Accumulation of driver and passenger mutations during tumor
progression. Proc Natl Acad Sci USA. 107:18545–18550. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kirchhoff M, Rose H, Petersen BL, Maahr J,
Gerdes T, Lundsteen C, Bryndorf T, Kryger-Baggesen N, Christensen
L, Engelholm SA and Philip J: Comparative genomic hybridization
reveals a recurrent pattern of chromosomal aberrations in severe
dysplasia/carcinoma in situ of the cervix and in advanced-stage
cervical carcinoma. Genes Chromosomes Cancer. 24:144–150. 1999.
View Article : Google Scholar
|
|
5
|
Heselmeyer K, Macville M, Schröck E,
Blegen H, Hellström AC, Shah K, Auer G and Ried T: Advanced-stage
cervical carcinomas are defined by a recurrent pattern of
chromosomal aberrations revealing high genetic instability and a
consistent gain of chromosome arm 3q. Genes Chromosomes Cancer.
19:233–240. 1997. View Article : Google Scholar
|
|
6
|
Xiao S, Zhou Y, Jiang J, Yuan L and Xue M:
CD44 affects the expression level of FOS-like antigen 1 in cervical
cancer tissues. Mol Med Rep. 9:1667–1674. 2014.
|
|
7
|
Ibrahim EM, Stewart RL, Corke K, Blackett
AD, Tidy JA and Wells M: Upregulation of CD44 expression by
interleukins 1, 4, and 13, transforming growth factor-beta1,
estrogen, and progestogen in human cervical adenocarcinoma cell
lines. Int J Gynecol Cancer. 16:1631–1642. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wobus M, Kuns R, Wolf C, Horn LC, Köhler
U, Sheyn I, Werness BA and Sherman LS: CD44 mediates constitutive
type I receptor signaling in cervical carcinoma cells. Gynecol
Oncol. 83:227–234. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scotto L, Narayan G, Nandula SV,
Subramaniyam S, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M,
Schneider A, Arias-Pulido H and Murty VV: Integrative genomics
analysis of chromosome 5p gain in cervical cancer reveals target
over-expressed genes, including Drosha. Mol Cancer.
7:582008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dowen SE, Neutze DM, Pett MR, Cottage A,
Stern P, Coleman N and Stanley MA: Amplification of chromosome 5p
correlates with increased expression of Skp2 in HPV-immortalized
keratinocytes. Oncogene. 22:2531–2540. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kloth JN, Oosting J, van Wezel T, Szuhai
K, Knijnenburg J, Gorter A, Kenter GG, Fleuren GJ and Jordanova ES:
Combined array-comparative genomic hybridization and
single-nucleotide polymorphism-loss of heterozygosity analysis
reveals complex genetic alterations in cervical cancer. BMC
Genomics. 8:532007. View Article : Google Scholar
|
|
12
|
Funaro A, Spagnoli GC, Ausiello CM,
Alessio M, Roggero S, Delia D, Zaccolo M and Malavasi F:
Involvement of the multi-lineage CD38 molecule in a unique pathway
of cell activation and proliferation. J Immunol. 145:2390–2396.
1990.PubMed/NCBI
|
|
13
|
Howard M, Grimaldi JC, Bazan JF, Lund FE,
Santos-Argumedo L, Parkhouse RM, Walseth TF and Lee HC: Formation
and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen
CD38. Science. 262:1056–1059. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malavasi F, Funaro A, Roggero S,
Horenstein A, Calosso L and Mehta K: Human CD38: a glycoprotein in
search of a function. Immunol Today. 15:95–97. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malavasi F, Deaglio S, Funaro A, Ferrero
E, Horenstein AL, Ortolan E, Vaisitti T and Aydin S: Evolution and
function of the ADP ribosyl cyclase/CD38 gene family in physiology
and pathology. Physiol Rev. 88:841–886. 2008. View Article : Google Scholar
|
|
16
|
Karimi-Busheri F, Zadorozhny V, Shawler DL
and Fakhrai H: The stability of breast cancer progenitor cells
during cryo-preservation: maintenance of proliferation,
self-renewal, and senescence characteristics. Cryobiology.
60:308–314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karimi-Busheri F, Zadorozhny V, Li T, Lin
H, Shawler DL and Fakhrai H: Pivotal role of CD38 biomarker in
combination with CD24, EpCAM, and ALDH for identification of H460
derived lung cancer stem cells. J Stem Cells. 6:9–20.
2011.PubMed/NCBI
|
|
18
|
Karimi-Busheri F, Zadorozhny V, Carrier E
and Fakhrai H: Molecular integrity and global gene expression of
breast and lung cancer stem cells under long-term storage and
recovery. Cell Tissue Bank. 14:175–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Malavasi F, Deaglio S, Damle R, Cutrona G,
Ferrarini M and Chiorazzi N: CD38 and chronic lymphocytic leukemia:
a decade later. Blood. 118:3470–3478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamblin TJ: CD38: what is it there for?
Blood. 102:1939–1940. 2003. View Article : Google Scholar
|
|
21
|
Jawad M, Yu N, Seedhouse CH, Tandon K,
Russell NH and Pallis M: Targeting of
CD34+CD38− cells using Gemtuzumab ozogamicin
(Mylotarg) in combination with tipifarnib (Zarnestra) in acute
myeloid leukaemia. BMC Cancer. 12:4312012.
|
|
22
|
Dürig J, Naschar M, Schmücker U,
Renzing-Köhler K, Hölter T, Hüttmann A and Dührsen U: CD38
expression is an important prognostic marker in chronic lymphocytic
leukaemia. Leukemia. 16:30–35. 2002.
|
|
23
|
Qiao M, Sheng S and Pardee AB: Metastasis
and Akt activation. Cell Cycle. 7:2991–2996. 2008. View Article : Google Scholar
|
|
24
|
Kreisberg JI, Malik SN, Prihoda TJ,
Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM: Phosphorylation of
Akt (Ser473) is an excellent predictor of poor clinical outcome in
prostate cancer. Cancer Res. 64:5232–5236. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Malik SN, Brattain M, Ghosh PM, Troyer DA,
Prihoda T, Bedolla R and Kreisberg JI: Immunohistochemical
demonstration of phospho-Akt in high Gleason grade prostate cancer.
Clin Cancer Res. 8:1168–1171. 2002.PubMed/NCBI
|
|
26
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hara A and Okayasu I: Cyclooxygenase-2 and
inducible nitric oxide synthase expression in human astrocytic
gliomas: correlation with angiogenesis and prognostic significance.
Acta Neuropathol. 108:43–48. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
30
|
IARC Globocan. Cervical Cancer Incidence
and Mortality Worldwide in 2008. http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
|
|
31
|
Alameda F, Espinet B, Corzo C, Muñoz R,
Bellosillo B, Lloveras B, Pijuan L, Gimeno J, Salido M, Solé F,
Carreras R and Serrano S: 3q26 (hTERC) gain studied by fluorescence
in situ hybridization as a persistence-progression indicator in
low-grade squamous intraepithelial lesion cases. Hum Pathol.
40:1474–1488. 2009. View Article : Google Scholar
|
|
32
|
Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC,
Whang-Peng J, Liu JM, Yang DM, Yang WK and Shen CY: PIK3CA as an
oncogene in cervical cancer. Oncogene. 19:2739–2744. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vazquez-Mena O, Medina-Martinez I,
Juárez-Torres E, Barrón V, Espinosa A, Villegas-Sepulveda N,
Gómez-Laguna L, Nieto-Martínez K, Orozco L, Roman-Basaure E, Muñoz
Cortez S, Borges Ibañez M, Venegas-Vega C, Guardado-Estrada M,
Rangel-López A, Kofman S and Berumen J: Amplified genes may be
overexpressed, unchanged, or downregulated in cervical cancer cell
lines. PLoS One. 7:e326672012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Andersson S, Wallin KL, Hellström AC,
Morrison LE, Hjerpe A, Auer G, Ried T, Larsson C and
Heselmeyer-Haddad K: Frequent gain of the human telomerase gene
TERC at 3q26 in cervical adenocarcinomas. Br J Cancer. 95:331–338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Perenkov AD, Novikov DV, Sakharnov NA,
Aliasova AV, Utkin OV, Baryshnikov AIu and Novikov VV:
Heterogeneous expression of CD38 gene in tumor tissue in patients
with colorectal cancer. Mol Biol (Mosk). 46:786–791. 2012.(In
Russian).
|
|
36
|
Albeniz I, Demir-Coşkun O, Türker-Şener L,
Baş A, Asoğlu O and Nurten R: CD38 expression as response of
hematopoietic system to cancer. Oncol Lett. 2:659–664.
2011.PubMed/NCBI
|
|
37
|
Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato
JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A
expression in hepatocellular carcinoma. J Clin Invest. 123:285–298.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang H, Fang F, Chang R and Yang L:
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting
transforming growth factor β receptor 1 and fibroblast growth
factor 9 in hepatocellular carcinoma. Hepatology. 58:205–217.
2013.PubMed/NCBI
|
